Engagement in Outpatient Care for Persons Living with HIV in the United States by Oramasionwu, Christine et al.
CLINICAL PERSPECTIVE
Engagement in Outpatient Care for Persons
Living with HIV in the United States
Christine Oramasionwu,1 Stacy Cooper Bailey,1 Terence L. Johnson,1 and Lu Mao2
Abstract
Prior studies that have assessed engagement within the various stages of care for persons living with HIV (PLWH)
studied patients receiving care in HIV medical care facilities. These data are not representative of care received
throughout the United States, as not all PLWH receive care in HIV clinics. This study evaluated engagement in
outpatient care and healthcare utilization for PLWH, beyond facilities that specialize in HIV. Cross-sectional data
were from the 2009–2010 National Hospital Ambulatory Medical Care Survey. Levels of care included receiving
any care, receiving HIV-related care, established in care, engaged in care, and prescribed antiretroviral therapy
(ARV). Factors associated with ARV prescription were determined by logistic regression. We analyzed data for
*2.6 million outpatient clinic visits for PLWH. Of these, 90% were receiving HIV-related care, 86% were
established in care, 75% were engaged in care, and 65% were prescribed ARV. In stratified analysis, the
proportion of PWLH who were engaged in care varied by race/ethnicity ( p < 0.001) and ARV prescription varied
significantly across the three age groups ( p = 0.004). Clinic visits within the past year did not differ for those
prescribed ARV vs. not prescribed ARV [median, IQR = 3.3 visits (1.8–5.6) vs. 3.6 visits (1.3–5.9); p = 0.7].
Seeing a physician was associated with ARV prescription (OR = 0.27, 95% CI = 0.15–0.51), whereas routine
engagement in care was not associated with ARV prescription (OR = 0.99, 95% CI = 0.96–1.03). Given that non-
ARV-treated PLWH utilized outpatient care services at rates similar to ARV-treated PLWH, these routine clinic
visits are missed opportunities for increasing ARV prescription in untreated patients.
Introduction
In 2013, the Department of Health and Human Services(DHHS) Panel on Antiretroviral Guidelines for Adults
and Adolescents recommended that antiretroviral therapy
(ARV) be initiated in all persons living with HIV (PLWH) in
order to reduce the risk of disease progression and HIV
transmission.1 The goal of ARV therapy is to inhibit HIV
replication and achieve viral load (VL) suppression. Viral
suppression is also an integral component of preventing HIV
transmission to uninfected individuals.2 However, approxi-
mately 25% of PLWH in the United States achieve viral load
suppression3; lack of access and poor engagement in routine
outpatient HIV medical care are cited as barriers to achieving
this outcome.4,5
The HIV cascade has recently emerged in the scientific
literature to illustrate how patients engage in the many stages
of the HIV care spectrum.6 HIV treatment requires routine
care and monitoring, however, PLWH often discontinue care
at different stages, which precludes them from achieving an
undetectable VL. Recent estimates from the National HIV
Surveillance System of the Centers for Disease Control and
Prevention (CDC) indicate that there are approximately 1.15
million PLWH in the United States, of which 940,000 (82%)
have diagnosed infection and of which only 287,000 (25%)
have undetectable VL.7 Other studies that have applied the
cascade to various patient populations report greater engage-
ment in care, with viral suppression rates as high as 70%.8,9
However, the CDC surveillance system and other studies were
restricted to patients receiving care in HIV specialty clinics.
Such clinics may not be representative of nonspecialty facili-
ties that provide care to PLWH in the United States; as such,
the generalizability of these findings beyond specialty care
settings is uncertain.
The HIV cascade not only reveals gaps in continuity of
care, but also illustrates the health inequities inherent in our
healthcare system. Certain subgroups of PLHW, particularly
racial/ethnic minorities, males, and those younger in age,
demonstrate lower engagement in the various stages of HIV
care and are also less likely to achieve viral suppression.7
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Our primary objective for this study was to estimate en-
gagement in outpatient care for PLWH who received services
from a broad range of facilities, beyond those that specialize
in HIV. Our secondary objectives were to document differ-
ences in engagement in care between groups by age, sex, and
race/ethnicity and to identify determinants of ARV coverage
among established patients visiting their usual source of care.
Lastly, we also examined the relationship between ARV
coverage, healthcare utilization, and clinic visit disposition.
Materials and Methods
Study design
Cross-sectional data from the 2009 and 2010 National
Hospital Ambulatory Medical Care Survey (NHAMCS) were
used to conduct this study. The NHAMCS is a nationwide
probability sample survey conducted by the CDC. Survey
data are available to the public and provide national repre-
sentations of annual hospital clinic visit records. The purpose
of NHAMCS is to provide a population-level estimation of
the utilization of outpatient services in the United States. The
data are collected through chart reviews conducted by trained
clinic personnel. The University of North Carolina Institu-
tional Review Board (IRB) reviewed the study protocol and
determined that this research was not considered Human
Subjects Research, therefore, IRB approval was not needed.
To identify PLWH within the NHAMCS dataset, we se-
lected patient records containing at least one of three Inter-
national Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) codes: 042 (HIV disease), V08
(asymptomatic HIV infection), or 079.53 (HIV-2 illness). We
excluded nonadult patients (age < 18 years of age at time of
clinic visit). Approximately 1.1% of the patient records that
met the age criteria had at least one of the three HIV disease
codes.
Outcomes
Healthcare utilization was calculated as the number of
clinic visits within the past year. The number of clinic visits
was collected through chart review and was exclusive to one
clinic. Levels of care included ‘‘receiving any care’’ ( ‡ 1
clinic visit for a PLWH), ‘‘receiving HIV care’’ ( ‡ 1 clinic
visit with a primary ICD-9-CM code for HIV), ‘‘established
in care’’ (patient previously seen within the clinic), and
‘‘engaged in care’’ ( ‡ 2 clinic visits in the past year). ‘‘Pre-
scribed ARV’’ was defined as the documentation of ‡ 1 ARV
medication in the clinic visit record. The dataset provides
data on up to eight medications that were prescribed (ordered,
supplied, administered, or continued) during the clinic visit.
Medications were identified using 5-digit codes located
within the CDC’s Ambulatory Care Drug Database System.10
‘‘Visit disposition’’ at the completion of the clinic visit was
classified as return to the clinic, refer to other physician, or
refer to the emergency department (ED) or hospital for ad-
mission, other, or no disposition documented. We calculated
the proportions of visits that were engaged in the various
levels of care using appropriate denominators for each level.7
The total number of visits meeting study criteria was used as
the denominator to calculate the proportion receiving HIV
care and the proportion established in care, whereas the
number of visits for PLWH established in care was used as
the denominator to calculate the proportion engaged in care
and the proportion prescribed ARV.
Covariates
Additional covariates included patient demographics [pa-
tient age at time of clinic visit (years), race/ethnicity, sex,
insurance status] and visit characteristics (clinic geographic
region in the United States, total number of visits to the clinic
in the past year, and patient comorbidities). Comorbidities
were measured using additional clinic visit diagnoses, and
included chronic renal failure, depression, hypertension, is-
chemic heart disease, hyperlipidemia, and diabetes.
Analyses
Statistical analyses were performed using standard survey
analysis methodology. Domain analysis is used for proper
estimation of variance based on the selected subpopulation.
National estimates of outpatient clinic visits were computed
using survey weights for each observation. We also com-
pared patient demographics and comorbidities between pa-
tients with and without ARV coverage, while accounting for
the stratifying and clustering effects of the principal sampling
units (PSUs). For categorical variables, the survey chi-square
tests were applied; for continuous variables, tests based on
the survey linear regression were used. Furthermore, we built
a survey logistic regression model predicting ARV pre-
scription based on important patient characteristics such as
age, sex, race/ethnicity, and geography. Additional visit
characteristics will also be included as covariates if they are
found to be significantly associated with ARV in the bivariate
analyses. All analyses were performed with SAS version 9.2
(SAS Institute, Cary, NC) using procedures SURVEYFREQ,
SURVEYMEANS, and SURVEYLOGISTIC, where appro-
priate.
Results
Using weighted observations, approximately 2.6 million
outpatient clinic visits for PLWH met study inclusion criteria.
Overall, engagement in care decreased across the progressing
levels of care, as illustrated in Fig. 1. Of PLWH with ‡ 1
clinic visits, 90% were receiving HIV-related care, 86% were
established in care, 75% were engaged in care, and 65% were
prescribed ARV.
The remaining results pertain to PLWH who were estab-
lished in care. In stratified analysis, which is presented in
Table 1, engagement in the various levels of care did not vary
significantly by sex. We found significant differences by
race/ethnicity in the proportion of PWLH engaged in care
( p < 0.001) and ARV prescription varied significantly across
the three age groups ( p = 0.004).
Differences in patient demographics and comorbidities, by
ARV status, are presented in Table 2. Physicians more fre-
quently provided care for untreated PLWH than treated PLWH
(91% vs. 77%; p < 0.01). The number of clinic visits within the
past year did not differ for visits prescribed ARV compared to
those not prescribed ARV [median, interquartile range (IQR)
3.3 visits (1.8–5.6) vs. 3.6 visits (1.3–5.9); p = 0.7].
Seeing a physician, compared to a nonphysician, at the time
of clinic visit was the only factor that was significantly asso-
ciated with ARV prescription (OR = 0.27, 95% CI = 0.15–0.51).
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An increasing number of clinic visits within the past year was
not associated with ARV prescription (OR = 0.99, 95% CI =
0.96–1.03), nor was visit with the primary care physician/
provider (OR = 1.18, 95% CI = 0.58–2.39). Full regression an-
alyses are presented in Table 3. The majority of PLWH were
instructed to return to the clinic at a specified time (98%).
Discussion
We estimated the levels of engagement in care for PLWH
in a broad setting of outpatient clinics in the United States.
Mapping the HIV care cascade in PLWH helps to ascertain
points for subsequent health interventions. As expected, en-
gagement declined with progressive levels of care; of those in
outpatient care, only 65% were prescribed ARV. Given that
non-ARV-treated PLWH utilized outpatient care services at
rates similar to ARV-treated PLWH, these routine clinic
visits are missed opportunities for promoting ARV use in
untreated patients. Of note, our study is representative only of
PLWH with diagnosed HIV infection already in care. Diag-
nosis is still the first step in the cascade; yet between 18% and
20% of HIV infections remain undiagnosed.7,11 This under-
scores the need for routine HIV testing for patients in all
healthcare settings.12,13
Overall, our findings are consistent with prior studies eval-
uating the continuum of care for PLWH that was conducted
during the same period of time.13 Hall et al.7 used 2009 data
from the CDC’s National HIV Surveillance System, a primary
source for HIV epidemiologic data in the United States, and
the Medical Monitoring Project (MMP), a nationwide sur-
veillance project to gather clinical and behavioral information
for PLWH. However, the MMP is restricted to outpatient HIV
specialty medical care facilities, whereas the NHAMCS is















































Engagement in Outpatient Care
FIG. 1. Levels of engage-
ment in outpatient care for
persons living with HIV in-
fection (PLWH) in the Uni-
ted States from 2009 to 2010.
Table 1. Engagement in Levels of Outpatient Care for Persons Living With HIV
Age group (years) Sex Race/ethnicity
18–29 30–49 ‡ 50 p-valuea Male Female p-valuea White Black Hispanic Other p-valuea
Receiving HIV-related
care, %b
84.9 89.2 92.3 0.360 91.0 85.7 0.102 90.5 86.5 94.1 81.3 0.237
Established in care among
PLWH receiving HIV
care, %b
78.7 86.5 89.0 0.217 87.6 82.5 0.187 88.5 84.1 87.5 80.8 0.702
Engaged in care among
PLWH established
in care, %c




57.4 82.7 71.3 0.004 78.6 65.0 0.274 81.0 67.1 80.2 83.3 0.092
ap-values are obtained from chi-square tests.
bNumber of visits meeting study criteria was used as the denominator.
cNumber of visits for PLWH established in care was used as the denominator.
PLWH, persons living with HIV; ARV, antiretroviral.
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analysis, only one-third of all PLWH were retained in care
(defined as having ‡ 1 medical care visit in a 4-month period).
They estimated that the majority (89%) of those retained in
care were prescribed ARV.
This high coverage of ARV is consistent when compared
to other studies that have studied HIV specialty medical care
facilities.4,8 It has also been demonstrated that clinics with
highly integrated healthcare systems (such as the VA system)
can attain even greater engagement at each of the stages of
care, when compared to these national estimates.14
In contrast, our study revealed that engagement in care was
lower in comparison to previous studies. We found that only
72% of those receiving HIV-related medical care were pre-
scribed ARV, a finding that is similar to estimates modeled by
Gardner et al.6 Although this finding is likely attributed to our
broader scope of outpatient facilities, it may also be a re-
flection of low ARV treatment utilization in nonspecialty
clinics. Historically, the predominant source of HIV care has
been in HIV/infectious diseases specialty clinics.15–17 Given
the numerous advances to combination ARV, HIV has now
Table 2. Characteristics for Persons Living With HIV Established in Care,








Population total (1,000) (95% CI) 2,237 (758–3,718) 1,684 (496–2,872) 553 (227–879) < 0.001
Patient demographics
Mean age (years) (95% CI) 44.4 (42.3–46.5) 44.7 (43.1–46.3) 43.4 (38.6–48.2) 0.514
Age (years) (%) — — — 0.004
18–29 12.9% 9.8% 22.1%
30–49 50.2% 55.1% 35.0%
‡ 50 36.9% 35.1% 42.9%
Sex (%) — — — 0.274
Male 75.7% 79.0% 65.6%
Female 24.3% 30.0% 34.4%
Race/ethnicity (%) — — — 0.092
White 31.0% 33.4% 23.8%
Black/African American 40.0% 35.7% 53.2%
Hispanic 27.5% 29.3% 22.0%
Other 1.5% 1.6% 1.0%
Geographic region (%) — — — NAb
Northeast 21.4% 21.2% 22.0%
Midwest 0.2% 0.2% 0
West 14.1% 13.4% 16.5%
South 64.3% 65.2% 61.5%
Insurance status (%) — — — 0.605
Private 20.8% 20.3% 22.2%
Medicare 22.4% 25.0% 14.5%
Medicaid 40.7% 38.0% 48.9%
Uninsured (self-pay, charity care) 3.3% 2.8% 4.6%
Other (other, unknown, worker’s compensation) 12.8% 13.9% 9.8%
Patient comorbidities
Hypertension (%) 30.1% 30.4% 29.1% 0.904
Ischemic heart disease (%) 1.0% 0.2% 3.6% 0.002
Hyperlipidemia (%) 19.8% 20.6% 17.2% 0.663
Chronic renal failure (%) 2.9% 1.6% 6.7% 0.142
Depression (%) 31.8% 33.3% 27.5% 0.256
Diabetes (%) 9.3% 8.3% 12.4% 0.450
Visit characteristics
Patient’s primary care physician/provider (%) — — — 0.407
Yes 38.8% 40.1% 35.0%
No 59.1% 58.6% 60.4%
Unknown 2.1% 1.3% 4.6%
Health care professional seen (%) — — —
Physician 80.5% 77.0% 91.3% < 0.001
RN/LPN 79.7% 79.5% 80.3% 0.917
Nurse practitioner/midwife 13.7% 14.2% 12.4% 0.705
Physician assistant 5.3% 6.9% 0.2% 0.134
Other 32.2% 31.5% 34.2% 0.689
ap-values are obtained from chi-square tests.
bNo test available because of too few unweighted observations in at least one cell.
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evolved into a chronic disease that can be managed in the
outpatient care setting.18 Nevertheless, there is still the need
for specialty training for any provider caring for PLWH,
particularly primary care providers practicing in nonspecialty
settings.19 Providers need to be well equipped to manage
treatment-related complications, such as drug toxicities, drug
resistance, waning adherence, and the yet unknown sequelae
of long-term therapy.18
We compared levels of care by select demographics and
found no differences by sex for any of the levels of engage-
ment. We found significant differences by race/ethnicity in
the proportion of PWLH who were engaged in care. Pre-
scription of ARV was lowest for blacks, but this finding was
not statistically significant. Although there were no differ-
ences in the proportions of PLWH receiving HIV care or
established in care across the age groups, younger adults were
less likely to be engaged in care or to be prescribed ARV
compared to older adults. This age disparity has been re-
ported elsewhere.7,8,20,21 According to CDC HIV surveil-
lance data, younger adults aged 15–29 years accounted for
only 10% of those living with diagnosed infection in the
United States, but accounted for 35% of all new infections
occurring in 2010 (16,000 estimated new infections).22 These
age differences in engagement and ARV coverage are likely a
reflection of lower rates of adherence in younger adults with
HIV infection.23 These findings highlight the need for age-
appropriate interventions to not only prevent HIV transmis-
sion in younger adults, but also to improve care retention and
treatment utilization.24 As expected, the majority of HIV
infections occurred in the southern region of the United
States.25 It has also been demonstrated that engagement and
retention in care vary widely by state and location in the
United States, underscoring the need to evaluate geographic
and localized gaps in the continuum of care.26
Prior studies have shown that lack of continuous engage-
ment in care is associated with noninitiation of ARV.8,27 In
contrast, the number of visits in the past year was not sig-
nificantly associated with ARV prescription in our study.
This implies that routine clinic visits may be missed oppor-
tunities to promote ARV use for PLWH, particularly those
seeking care in nonspecialty clinics. In light of recent DHHS
treatment recommendations, outpatient providers are en-
couraged to initiate patients on ARV when they come in to
receive HIV medical care. This reinforces the need for out-
patient providers to receive the necessary training and ex-
pertise to best manage these patients.
This study is subject to some limitations related to the na-
ture of the NHAMCS and limitations of cross-sectional
studies. Within the NHAMCS, it is not possible to differen-
tiate HIV/infectious diseases specialty clinics from non-
specialty clinics. This possibility of confounding is limited
since PLWH should receive the same standard of medical care
regardless of the medical facility. The data presented in these
surveys represent national, population-level estimates rather
than patient-level estimates. Each weighted observation rep-
resents a clinic visit, rather than a patient; it is possible that a
single patient represents multiple clinic visits leading to
possible selection bias. The complex multistage sampling
design reduces the likelihood that an individual patient is
sampled more than once during the 4-week sampling period.
This was a cross-sectional study. Patients were not followed
longitudinally, thus long-term outcomes were not available.
However, data regarding clinic disposition were available.
Our analysis of HIV care may not be directly comparable
to other standard retention definitions that have been applied
in cohort studies.28 Rather, our measures of healthcare utili-
zation were based on patients previously receiving care at the
clinic, the number of documented clinic visits in the past year,
and documentation of any antiretroviral medications at the
time of the clinic visit. Objective laboratory markers, such as
CD4 + and HIV-1 RNA, were not collected as part of the
survey design; therefore it was not possible to determine
ARV eligibility based on CD4 + or the effectiveness of ARV
based on HIV VL. Data from this study were from 2009–
2010 and might not capture the current landscape for ARV
coverage. Treatment guideline recommendations now en-
dorse ARV in all PLWH, regardless of CD4 + count. Limited
research is available to determine how this change in
guideline recommendations will shift clinical practices.
In the changing landscape of ARV treatment guidelines,
more research is needed to understand factors deciding when
a PLWH is prescribed ARV. Given that non-ARV-treated
PLWH utilized outpatient care services at rates similar to
ARV-treated PLWH, these routine clinic visits are missed
opportunities for increasing ARV prescription in untreated
patients.
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